rhTPO, as a recombinant analog of endogenous thrombopoietin, directly mimics physiological TPO activity, but its short half-life necessitates frequent dosing, which may compromise adherence in chronic ITP management (31). This evidence concerns the gene THPO and autoimmune thrombocytopenic purpura.